Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,474 across all filing types
Latest filing 2020-03-11 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from Ascletis Pharma Inc. regarding a scheduled board meeting to consider and approve the annual results for the year ended December 31, 2019, and to consider the recommendation of a final dividend. It does not contain the actual annual report or financial data but merely announces the meeting date and agenda. The document length is only 1418 characters, indicating it is a brief notice rather than a full report. According to the 'MENU VS MEAL' rule, such announcements about upcoming report approvals are classified as Regulatory Filings (RNS) rather than the report itself (10-K or Annual Report). Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-03-11 English
ANNOUNCEMENT - INSIDE INFORMATION - PROGRESS OF THE SMALL SAMPLE CLINICAL TRIAL OF GANOVO (DANOPREVIR) AND RITONAVIR COMBINATION THERAPY ON NOVEL CORONAVIRUS PNEUMONIA
Regulatory Filings Classification · 95% confidence The document is an announcement by Ascletis Pharma Inc. regarding the progress of a small sample clinical trial of a drug combination therapy for Novel Coronavirus Pneumonia. It references regulatory rules (Rule 13.09 of the Listing Rules) and is labeled as an "announcement". The content is informational about clinical trial progress and does not contain financial statements, detailed financial data, or management discussion. The document length is 3065 characters, which is relatively short and typical for an announcement rather than a full report. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory certification or officer attestation. The document is a regulatory announcement about inside information related to clinical trial progress, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-03-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2020
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 29/2/2020, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. It includes confirmations by the company secretary regarding compliance with listing rules and legal requirements. The content focuses on share capital changes and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting monthly share capital movements and confirmations, not a full financial report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2020-03-03 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 29 February 2020
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 29/2/2020, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content is focused on changes in the company's share capital structure during a specific month. There are no financial statements, earnings data, management discussion, or audit information. The document is a regulatory filing reporting share capital movements, typical for compliance with exchange rules. It is not an announcement of a report, nor a full financial report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2020-03-02 English
ANNOUNCEMENT - INSIDE INFORMATION - CLINICAL TRIAL OF GANOVO AND RITONAVIR COMBINATION THERAPY ON NOVEL CORONAVIRUS PNEUMONIA
Regulatory Filings Classification · 95% confidence The document is an announcement by Ascletis Pharma Inc. regarding clinical trial information related to Ganovo and Ritonavir combination therapy for Novel Coronavirus Pneumonia. It references regulatory rules (Rule 13.09 of the Listing Rules) and inside information provisions, indicating it is a regulatory announcement. The document is relatively short (3436 characters) and does not contain financial statements or detailed financial data. It is not a report but an announcement of inside information related to clinical trials and drug development progress. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-02-27 English
APPLICATION FOR CATEGORY I DRUG ASC41 FOR CLINICAL TRIALS OF NONALCOHOLIC STEATOHEPATITIS (NASH) INDICATION ACCEPTED
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the acceptance of an application for clinical trials of a drug (ASC41) by China's National Medical Products Administration. It is a short announcement (1993 characters) and does not contain financial data, regulatory certifications, or detailed report content. It is not an annual or interim report, earnings release, or any detailed financial or governance document. It is also not a voting result, director dealing, or capital change notice. The content is a regulatory update about a drug application acceptance, which fits best under a general regulatory announcement category. Given the short length and nature, it is not a report publication announcement but a regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-02-18 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.